Characterization of adrenal metastatic cancer using FDG PET/CT.

The adrenal gland is a common location for metastasis from a primary tumor in another organ. This study evaluated the properties of adrenal lesions in cancer and non-cancer patients and investigated what variables may help predict adrenal metastasis. This retrospective study used 18fluorodeoxyglucose PET/CT on 371 patients with adrenal lesions (N = 260 with a primary tumor and N= 111 with an unknown primary tumor). Parameters such as the presence of a tumor, nodule, enlarged adrenal, maximum standardized uptake (SUVmax ratio) were evaluated. Univariate and multivariate analysis were used to identify variables that may predict risk of adrenal metastasis. Subjects with adrenal metastasis versus those without had a higher frequency of primary lung tumors (53.7% versus 28.6%, respectively; P≤ 0.001) but a lower frequency of gastrointestinal cancer (9.3% versus 20.4%, respectively; P = 0.014). The frequency of other abnormalities including nodules and enlarged adrenals were similar between cancer and non-cancer subjects. A higher proportion of subjects with adrenal metastasis regardless whether the primary tumor site in the lung, gastrointestinal track, or liver had SUVmax ratio > 2.5 versus those with no adrenal metastasis. In this cohort of subjects, the greatest proportion of subjects with adrenal metastasis was those with primary lung cancer. Univariate and multivariate analysis indicated that age, SUVmax ratio, and the presence of metastasis in multiple organs were independent variables for having adrenal metastasis. In this study, FDG PET/CT was useful in characterizing adrenal lesions including determining whether they were benign or malignant. This technology allowed us to identify characteristics that may useful in predicting adrenal metastasis and cancer severity.

[1]  S. Hoffe,et al.  Management of isolated Adrenal Lesions in Cancer Patients. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[2]  C. Leux,et al.  18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  H. Höffken,et al.  Incidental Non-Secreting Adrenal Masses in Cancer Patients: Intra-Individual Comparison of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography with Computed Tomography and Shift Magnetic Resonance Imaging , 2010, The Journal of international medical research.

[4]  W. Huang,et al.  18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients. , 2010, Neoplasma.

[5]  S. Kumano,et al.  Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions , 2009, Annals of nuclear medicine.

[6]  N. Holalkere,et al.  PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. , 2009, AJR. American journal of roentgenology.

[7]  R. Munver,et al.  Surgical management of metastases to the adrenal gland: Open, laparoscopic, and ablative approaches , 2009, Current urology reports.

[8]  O. Mundler,et al.  Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  J. Choi,et al.  Comparison of Delayed Enhanced CT and 18F-FDG PET/CT in the Evaluation of Adrenal Masses in Oncology Patients , 2007, Journal of computer assisted tomography.

[10]  W. Young The incidentally discovered adrenal mass , 2007 .

[11]  Bonnie N Joe,et al.  Adrenal masses: CT characterization with histogram analysis method. , 2003, Radiology.

[12]  Melvyn Korobkin,et al.  Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. , 2002, Radiology.

[13]  H. Ishizaka,et al.  Adrenal masses: differentiation with chemical shift, fast low-angle shot MR imaging. , 1993, Radiology.